Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer

Kazuyuki Yuge, Akira Miyajima, Nobuyuki Tanaka, Suguru Shirotake, Takeo Kosaka, Eiji Kikuchi, Mototsugu Oya

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background. To determine whether the administration of renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), affect disease outcome in non-muscle-invasive bladder cancer (NMIBC). Methods. A total of 330 patients with initially diagnosed NMIBC were identified. We retrospectively investigated the clinical outcomes after transurethral resection of bladder tumor (TUR-BT) in patients who did or did not receive RAS inhibitors. The median follow-up period was 4.1 years. Results. A total of 128 patients (38.8 %) experienced subsequent tumor recurrence, and stage progression was observed in 17 patients (5.2 %) during follow-up. Fifty-one patients (15.5 %) had received ACEI or ARB administration at transurethral resection. Multivariate analysis demonstrated that tumor multiplicity, absence of bacillus Calmette-Guérin instillation, and no administration of ACEI or ARB (P = 0.010, hazard ratio 2.26) were independent risk factors for subsequent tumor recurrence. The 5-year recurrence-free survival rate was 78.4 % in patients administered ACEIs or ARBs, and 53.3 % in their counterparts (P = 0.011). Conclusions. The absence of RAS inhibitor administration was an independent risk factor for subsequent tumor recurrence in patients with initially diagnosed NMIBC. Our data support further investigation of the role of RAS inhibitors as a potential therapy to decrease tumor recurrence in NMIBC.

Original languageEnglish
Pages (from-to)3987-3993
Number of pages7
JournalAnnals of Surgical Oncology
Volume19
Issue number12
DOIs
Publication statusPublished - 2012 Nov

Fingerprint

Renin-Angiotensin System
Urinary Bladder Neoplasms
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Recurrence
Neoplasms
Bacillus
Multivariate Analysis
Survival Rate

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. / Yuge, Kazuyuki; Miyajima, Akira; Tanaka, Nobuyuki; Shirotake, Suguru; Kosaka, Takeo; Kikuchi, Eiji; Oya, Mototsugu.

In: Annals of Surgical Oncology, Vol. 19, No. 12, 11.2012, p. 3987-3993.

Research output: Contribution to journalArticle

Yuge, Kazuyuki ; Miyajima, Akira ; Tanaka, Nobuyuki ; Shirotake, Suguru ; Kosaka, Takeo ; Kikuchi, Eiji ; Oya, Mototsugu. / Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 12. pp. 3987-3993.
@article{4731b6b7628b49c3bb7babb6cd2d34ca,
title = "Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer",
abstract = "Background. To determine whether the administration of renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), affect disease outcome in non-muscle-invasive bladder cancer (NMIBC). Methods. A total of 330 patients with initially diagnosed NMIBC were identified. We retrospectively investigated the clinical outcomes after transurethral resection of bladder tumor (TUR-BT) in patients who did or did not receive RAS inhibitors. The median follow-up period was 4.1 years. Results. A total of 128 patients (38.8 {\%}) experienced subsequent tumor recurrence, and stage progression was observed in 17 patients (5.2 {\%}) during follow-up. Fifty-one patients (15.5 {\%}) had received ACEI or ARB administration at transurethral resection. Multivariate analysis demonstrated that tumor multiplicity, absence of bacillus Calmette-Gu{\'e}rin instillation, and no administration of ACEI or ARB (P = 0.010, hazard ratio 2.26) were independent risk factors for subsequent tumor recurrence. The 5-year recurrence-free survival rate was 78.4 {\%} in patients administered ACEIs or ARBs, and 53.3 {\%} in their counterparts (P = 0.011). Conclusions. The absence of RAS inhibitor administration was an independent risk factor for subsequent tumor recurrence in patients with initially diagnosed NMIBC. Our data support further investigation of the role of RAS inhibitors as a potential therapy to decrease tumor recurrence in NMIBC.",
author = "Kazuyuki Yuge and Akira Miyajima and Nobuyuki Tanaka and Suguru Shirotake and Takeo Kosaka and Eiji Kikuchi and Mototsugu Oya",
year = "2012",
month = "11",
doi = "10.1245/s10434-012-2568-z",
language = "English",
volume = "19",
pages = "3987--3993",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer

AU - Yuge, Kazuyuki

AU - Miyajima, Akira

AU - Tanaka, Nobuyuki

AU - Shirotake, Suguru

AU - Kosaka, Takeo

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

PY - 2012/11

Y1 - 2012/11

N2 - Background. To determine whether the administration of renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), affect disease outcome in non-muscle-invasive bladder cancer (NMIBC). Methods. A total of 330 patients with initially diagnosed NMIBC were identified. We retrospectively investigated the clinical outcomes after transurethral resection of bladder tumor (TUR-BT) in patients who did or did not receive RAS inhibitors. The median follow-up period was 4.1 years. Results. A total of 128 patients (38.8 %) experienced subsequent tumor recurrence, and stage progression was observed in 17 patients (5.2 %) during follow-up. Fifty-one patients (15.5 %) had received ACEI or ARB administration at transurethral resection. Multivariate analysis demonstrated that tumor multiplicity, absence of bacillus Calmette-Guérin instillation, and no administration of ACEI or ARB (P = 0.010, hazard ratio 2.26) were independent risk factors for subsequent tumor recurrence. The 5-year recurrence-free survival rate was 78.4 % in patients administered ACEIs or ARBs, and 53.3 % in their counterparts (P = 0.011). Conclusions. The absence of RAS inhibitor administration was an independent risk factor for subsequent tumor recurrence in patients with initially diagnosed NMIBC. Our data support further investigation of the role of RAS inhibitors as a potential therapy to decrease tumor recurrence in NMIBC.

AB - Background. To determine whether the administration of renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), affect disease outcome in non-muscle-invasive bladder cancer (NMIBC). Methods. A total of 330 patients with initially diagnosed NMIBC were identified. We retrospectively investigated the clinical outcomes after transurethral resection of bladder tumor (TUR-BT) in patients who did or did not receive RAS inhibitors. The median follow-up period was 4.1 years. Results. A total of 128 patients (38.8 %) experienced subsequent tumor recurrence, and stage progression was observed in 17 patients (5.2 %) during follow-up. Fifty-one patients (15.5 %) had received ACEI or ARB administration at transurethral resection. Multivariate analysis demonstrated that tumor multiplicity, absence of bacillus Calmette-Guérin instillation, and no administration of ACEI or ARB (P = 0.010, hazard ratio 2.26) were independent risk factors for subsequent tumor recurrence. The 5-year recurrence-free survival rate was 78.4 % in patients administered ACEIs or ARBs, and 53.3 % in their counterparts (P = 0.011). Conclusions. The absence of RAS inhibitor administration was an independent risk factor for subsequent tumor recurrence in patients with initially diagnosed NMIBC. Our data support further investigation of the role of RAS inhibitors as a potential therapy to decrease tumor recurrence in NMIBC.

UR - http://www.scopus.com/inward/record.url?scp=84868146869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868146869&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2568-z

DO - 10.1245/s10434-012-2568-z

M3 - Article

C2 - 22872290

AN - SCOPUS:84868146869

VL - 19

SP - 3987

EP - 3993

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -